We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study of Retrovir in the Treatment of Psoriasis in HIV-Positive Patients

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00002286
First Posted: August 31, 2001
Last Update Posted: December 9, 2005
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
NIH AIDS Clinical Trials Information Service
November 2, 1999
August 31, 2001
December 9, 2005
Not Provided
Not Provided
Not Provided
Not Provided
No Changes Posted
Not Provided
Not Provided
Not Provided
Not Provided
 
A Study of Retrovir in the Treatment of Psoriasis in HIV-Positive Patients
Retrovir Capsules in the Treatment of Psoriasis in HIV Antibody Positive Patients: A Pilot Study
To evaluate the feasibility of Retrovir (AZT) in the treatment of psoriasis in HIV antibody positive patients. Retrovir has been shown to be effective in the treatment of AIDS. In addition, the administration of AZT appears to have induced a remission of psoriasis in one case study. In light of AZT's antiviral activity and potential effectiveness as an agent for the treatment of psoriasis, this would be the most likely treatment for HIV positive, psoriatic patients whose disease progresses quickly.
Not Provided
Interventional
Not Provided
Primary Purpose: Treatment
  • HIV Infections
  • Psoriasis
Drug: Zidovudine
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
Not Provided
Not Provided
Not Provided

Inclusion Criteria

Study participants must have biopsy-proven psoriasis with 3 distinct psoriatic lesions. (Biopsy-proven Reiter's syndrome patients with 3 distinct cutaneous lesions may be included.) Documented HIV antibody (by federally licensed ELISA test) positive patients.

Prior Medication:

Allowed:

  • Zidovudine (AZT).

Exclusion Criteria

Co-existing Condition:

Patients with the following are excluded:

  • Presence of any active opportunistic infection.
  • Presence of any AIDS-defining neoplasms (excluding Kaposi's sarcoma) such as central nervous system (CNS) lymphoma.
  • Known hypersensitivity to zidovudine (AZT).
  • Impaired renal function.
  • Significant hepatic dysfunction.

Concurrent Medication:

Excluded:

- Topical steroid, anthralin, or tar preparations. Etretinate, methotrexate, or psoralen ultraviolet A (PUVA) therapy. Psoriatic treatment such as systemic agents or topical steroids (emollients used distal to the control lesions and antipruritic shampoos are admissible).

Patients with the following are excluded:

  • Presence of any active opportunistic infection.
  • Presence of any AIDS-defining neoplasms (excluding Kaposi's sarcoma) such as central nervous system (CNS) lymphoma.
  • Known hypersensitivity to zidovudine (AZT).
  • Impaired renal function.
  • Significant hepatic dysfunction.

Prior Medication:

Excluded:

  • Other antiretroviral agents (e.g., suramin, ribavirin, HPA-23, dideoxycytidine).
  • Excluded within 2 weeks of study entry:
  • Topical steroid, anthralin, or tar preparations.
  • Any other experimental therapy drugs which cause significant bone marrow suppression such as antifolates or pyrimethamine.
  • Cytolytic chemotherapy.
  • Drugs which cause significant nephrotoxicity or hepatotoxicity.
  • Rifampin or rifampin derivatives.
  • Excluded within 4 weeks of study entry:
  • Etretinate, methotrexate, or psoralen ultraviolet A (PUVA) therapy.
  • Excluded within 8 weeks of study entry:
  • Immunomodulating agents, including steroids, interferon, Isoprinosine, and interleukin 2.
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
United States
 
 
NCT00002286
014F
16
Not Provided
Not Provided
Not Provided
Not Provided
Glaxo Wellcome
Not Provided
Not Provided
NIH AIDS Clinical Trials Information Service
September 1989

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP